Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability & Effects of Rolipram in Multiple Sclerosis
NCT00011375Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Feb 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of (R)-Rolipram in multiple sclerosis (MS), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Safety and Tolerability of Rolipram at 8 months and Number of Gadolinium-enhancing lesions on MRI. Started Feb 2001; status: completed.
02
Drugs
(R)-Rolipram
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00011375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00011375.